Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)

Faivre-Finn, Corinne (Corresponding participant)

Division of Cancer Sciences (L5)

Impact: Health and wellbeing

Narrative

Our research as part of the international phase 3 randomised controlled trial (PACIFIC) showed that the addition of immunotherapy durvalumab (known as Imfinzi) after concurrent chemo-radiotherapy significantly improves progression free and overall survival in stage 3 NSCLC.

Corinne Faivre-Finn was the UK Chief Investigator, contributed to the protocol and presented the study at European Society for Medical Oncology (ESMO) conference in 2018.

The study was practice changing and in 2018 led to the approval of Durvalumab by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Ministry of Health, Labour and Welfare (MHLW) in Japan in unresectable stage III NSCLC.

Impact date	2018
Category of impact	Health and wellbeing
Impact level	Adoption

Research Beacons, Institutes and Platforms

Cancer
Manchester Cancer Research Centre

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)

Narrative

Research Beacons, Institutes and Platforms

Related content

Research output

Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC

Outcomes With Durvalumab after Chemoradiotherapy in Stage IIIA-N2 Non-small-cell Lung Cancer: an Exploratory Analysis from the PACIFIC Trial

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial